Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 3/20 | 0.31 |
| ▸ | FAP | Q12884 | 2/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.31 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385712 | 0.92 | L3MBTL1 (0.36) | LTA4HDPP7L3MBTL1CHRM1MME | |
| SCHEMBL385711 | 0.92 | L3MBTL1 (0.36) | LTA4HDPP7L3MBTL1CHRM1MME | |
| SCHEMBL383047 | 0.90 | L3MBTL1 (0.39) | LTA4HDPP7L3MBTL1CHRM1MME | |
| SCHEMBL383046 | 0.90 | L3MBTL1 (0.39) | LTA4HDPP7L3MBTL1CHRM1MME | |
| Threonine SCHEMBL4955781 | 0.86 | SLC7A5 (0.36) | LTA4HDPP7SLC7A5DPP4PREP | |
| Glycine SCHEMBL4955873 | 0.85 | GLRA1 (0.36) | LTA4HDPP7L3MBTL1CHRM1MME | |
| Serine SCHEMBL4956028 | 0.84 | DPP7 (0.40) | LTA4HDPP7L3MBTL1SLC7A5CHRM1 | |
| Pyrrole SCHEMBL28327955 | 0.78 | L3MBTL1 (0.38) | L3MBTL1HTT | |
| SCHEMBL4958317 | 0.75 | CASR (0.34) | SLC7A5 | |
| SCHEMBL4956023 | 0.75 | DPP7 (0.38) | LTA4HDPP7L3MBTL1SLC7A5RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7439226-B2 | Serine protease inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-10-21 | — | — | US | disclosed |
| WO-2006043933-A1 | SERINE PROTEASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050130883-A1 | Serine protease inhibitors | THE GOV. OF THE USA AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130883-A1 | Serine protease inhibitors | PRSS1, TASP1, METAP1 | LTA4H 1884/4885DPP7 173/4885L3MBTL1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.